Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

Gwenael Ferron,Gaëtan de Rauglaudre,Annick Chevalier,P. Combe,Florence Joly,Alain Lortholary,N. Raban,Salima Hamizi,E. Malaurie,Marie Christine Kaminsky,Patricia Pautier,J. Meunier,Jérôme Alexandre,Dominique Berton-Rigaud,Anne Floquet,Laurence Venat-Bouvet,Laure Favier,N. Dohollou,Coraline Dubot,Isabelle Ray-Coquard

Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study.

2019

5512Background: Nintedanib, an oral inhibitor of VEGF-FGF-PDGF receptors, has been shown to prolong progression-free survival (PFS) when added to adjuvant chemotherapy after primary surgery (duBois...

Keywords:

Ovarian cancer
Oncology
Pathology
Chemotherapy
Nintedanib
Internal medicine
Medicine
double blind
epithelial ovarian cancer
adjuvant chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations